645 ELL targets c-Myc for proteasomal degradation and suppresses tumour growth.
http://www.nature.com/ncomms/2016/160324/ncomms11057/full/ncomms11057.html
644 Tracing the fate of circulating tumour cells by intravital two-photon lung imaging shows that tumours produce microparticles as they arrive and these migrate along the lung vasculature and are mostly taken up by interstitial myeloid cells, in a process that contributes to metastatic seeding; a minor subset of microparticles is engulfed by conventional dendritic cells, which are thought to contribute to the initiation of an anti-tumour immune response in lung-draining lymph nodes.
http://www.nature.com/nature/journal/v531/n7595/full/nature16985.html
643 A known oncogene, MITF, resides in a region of chromosome 3 that is amplified in melanomas and associated with poor prognosis; now, a long non-coding RNA gene, SAMMSON, is shown to also lie in this region, to also act as a melanoma-specific survival oncogene, and to be a promising therapeutic target for anti-melanoma therapy.
http://www.nature.com/nature/journal/v531/n7595/full/nature17161.html
642 Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.
http://www.nature.com/nature/journal/v531/n7595/full/nature17157.html
641 Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma.
http://stm.sciencemag.org/content/8/328/328ra27.abstract
640 Tumor-initiating cells differentiate to a more benign state when treated with drugs that activate protein kinase A.
http://science.sciencemag.org/content/351/6277/aad3680
639 High-fat diet enhances stemness and tumorigenicity of intestinal progenitors.
http://www.nature.com/nature/journal/v531/n7592/full/nature17173.html
638 Tailoring nanoparticle designs to target cancer based on tumor pathophysiology.
http://www.pnas.org/content/113/9/E1142.abstract
637 Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.
http://www.pnas.org/content/113/7/E874.abstract
636 Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers.
http://www.pnas.org/content/113/7/1778.abstract
635 Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release.
http://www.pnas.org/content/113/7/1877.abstract
634 Mode of action and resistance studies unveil new roles for tropodithietic acid as an anticancer agent and the γ-glutamyl cycle as a proton sink.
http://www.pnas.org/content/113/6/1630.abstract
633 Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.
http://stm.sciencemag.org/content/8/325/325ra17.abstract?_ga=1.44396972.901395532.1409089406
632 An oligoclonal antibody overcomes drug resistance in colorectal cancers with EGFR mutations.
http://stm.sciencemag.org/content/8/324/324ra14
631 Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.
http://www.nature.com/ncomms/2016/160202/ncomms10391/full/ncomms10391.html
630 Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma.
http://www.nature.com/ncomms/2016/160202/ncomms10593/full/ncomms10593.html
629 Stochastic modeling reveals an evolutionary mechanism underlying elevated rates of childhood leukemia.
http://www.pnas.org/content/113/4/1050.abstract
628 A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation.
http://science.sciencemag.org/content/351/6272/aad2197.abstract
627 Structural details of how oncogenic human papilloma viruses induce cancer by targeting the tumour suppressor p53 for ubiquitin-mediated degradation.
http://www.nature.com/nature/journal/v529/n7587/full/nature16481.html
626 SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis.
http://www.pnas.org/content/113/3/638.abstract
|
